RAPP241220C17500
- 0.00
- 0.000.00%
Rapport Therapeutics Newsroom
Promising Developments and Strategic Focus Bolster Buy Rating for Rapport Therapeutics
Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting
TD Cowen Maintains Rapport Therapeutics(RAPP.US) With Buy Rating
Rapport Therapeutics, Inc. (RAPP) Gets a Buy From TD Cowen
Rapport Therapeutics | 10-Q: Quarterly report
Rapport Therapeutics Expects Cash to Fund Requirements Through 2026
Rapport Therapeutics Adds New Members to Board of Directors
Express News | Rapport Therapeutics Inc Q3 Shr View $-0.58 -- LSEG IBES Data
Rapport Therapeutics 3Q Loss/Shr 50c >RAPP
Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update
Press Release: Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update
Express News | Johnson & Johnson Reports 6.8% Passive Stake in Rapport Therapeutics Inc as of Sept 30- SEC Filing
This Rapport Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Rapport Therapeutics Analyst Ratings
Rapport Therapeutics Initiated With a Buy at JonesResearch
JonesTrading Initiates Rapport Therapeutics(RAPP.US) With Buy Rating, Announces Target Price $42
Promising Growth and Innovation Drive Buy Recommendation for Rapport Therapeutics, Inc.: Focus on RAP-219 and Strategic Collaborations
Jefferies Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $35
Buy Rating Affirmed for Rapport Therapeutics Amid Promising Phase IIa Epilepsy Study and RAP-219's Market Potential
Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences